Retroscreen Virology Group PLC hVIVO HCM of AL-8176 in RSV for Alios BioPharma
28 Juillet 2014 - 8:00AM
RNS Non-Regulatory
TIDMRVG
Retroscreen Virology Group PLC
28 July 2014
For immediate release 07.00: 28 July 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
RETROSCREEN CONDUCTS LANDMARK hVIVO HUMAN CHALLENGE MODEL STUDY
OF AL-8176 IN RSV FOR ALIOS BIOPHARMA
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
Human Challenge Models ("HCMs") of disease, acknowledges the
announcement by Alios BioPharma Inc. of positive results from a
landmark human viral challenge study of its oral anti-RSV
nucleoside analog AL-8176 in Respiratory Syncytial Virus ("RSV")
infection that was conducted by Retroscreen. This study is
considered to be a major endorsement of the clinical utility of
Retroscreen's hVIVO platform, in rapidly establishing proof of
concept and dose-ranging for investigational new drugs early on in
their development lifecycle.
The study was a randomized, double-blind, placebo-controlled
Phase 2 challenge study of AL-8176 in healthy adult volunteers, who
were infected intranasally with RSV. AL-8176 achieved its primary
and secondary endpoints of reduction in viral load (p<0.0002),
and improvement in symptom scores (p<0.02), as compared to
placebo. AL-8176 was well tolerated, with no discontinuations of
study drug and no clinically significant laboratory
abnormalities.
This viral HCM study was conducted by Retroscreen at its purpose
built, state-of-the-art clinical quarantine unit in London, UK. It
utilised an adaptive design and enrolled a total of 62 subjects
across 3 quarantine periods. The study started in January 2014 and
was conducted by Retroscreen in a little under 6 months.
Kym Denny, Chief Executive Officer, commented, "This study of
Alios' AL-8176 product for RSV infection, conducted by Retroscreen
in just under 6 months, highlights hVIVO's ability to surpass
field-based studies in producing clean compelling data in an
accelerated timeframe, through targeted subject recruitment and
defined timing of infection. The ability to accelerate the
development of new drugs underpins our expansion into new HCMs,
including for respiratory diseases such asthma and Chronic
Obstructive Pulmonary Disease (COPD)".
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
About Retroscreen
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1700 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness better because the
Company believes that the best way to understand human disease is
by studying it in humans, not laboratory models.
About Alios BioPharma
Alios BioPharma is a clinical stage biopharmaceutical company in
South San Francisco, CA that is developing novel antiviral
therapies for the treatment of respiratory diseases. The Alios
virology discovery and development platform consists of a
proprietary chemical library of nucleoside analogs as well as
novel, proprietary virology-based screening systems. Alios is
developing a portfolio of potential therapeutics for viral
infections including respiratory syncytial virus (RSV), influenza,
rhinovirus and coronavirus.
For more information please visit www.aliosbiopharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMGZNRNKGDZM
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024